ライフサイエンスコーパス: liposomal doxorubicin

1 n-bevacizumab regimen: carboplatin-pegylated liposomal doxorubicin.

2 90 degrees C RF dose either with or without liposomal doxorubicin.

3 ribution of the intratumoral accumulation of liposomal doxorubicin.

4 ry of systemic antineoplastic agents such as liposomal doxorubicin.

5 and toxicity outcomes also favored pegylated-liposomal doxorubicin.

6 atients who were then treated with pegylated-liposomal doxorubicin.

7 ess in predicting the tumour accumulation of liposomal doxorubicin.

8 nicopan display poor efficacy with PEGylated liposomal doxorubicin.

9 pheroids in a 3D printed fluidic device with liposomal doxorubicin.

10 M with equivalent concentrations of free and liposomal doxorubicin.

11 -Bro) potentiates the anti-tumor efficacy of liposomal doxorubicin.

12 ding an additional anti-tumor adjuvant agent liposomal doxorubicin.

13 eekly doses of gemcitabine, vinorelbine, and liposomal doxorubicin.

14 on was sufficient to increase sensitivity to liposomal doxorubicin.

15 after intravenous administration of (99m)Tc-liposomal doxorubicin.

16 subsequently, the animals were treated with liposomal doxorubicin.

17 n of therapeutic responsiveness of tumors to liposomal doxorubicin.

18 thin 3 months of discontinuing, topotecan or liposomal doxorubicin.

19 treated with RF ablation (2.3 cm +/- 0.1) or liposomal doxorubicin (0.0 cm +/- 0.0) alone (P < .01).

20 Intravenous liposomal doxorubicin (1 mg in 500 micro L, n = 6) or in

21 r RF (70 degrees C for 5 minutes) alone, (b) liposomal doxorubicin (1 mg) alone, (c) RF ablation foll

22 es, 2000-mA pulsed technique) followed by IV liposomal doxorubicin (10 mg per animal) (n = 6), RF abl

23 ved doxorubicin, epirubicin or non-pegylated liposomal-doxorubicin (10 mg/kg) and cardiac function wa

24 norelbine (20 mg/m(2) IV, days 1 and 8), and liposomal doxorubicin (15 mg/m(2), days 1 and 8), given

25 (n=8, each) that received a combined RF and liposomal doxorubicin (15 min post-RF, 8 mg/kg) either w

26 aclitaxel, capecitabine (CAPE), or pegylated liposomal doxorubicin; (2) for taxane- and anthracycline

27 valuated rituximab 375 mg/m(2) combined with liposomal doxorubicin 20 mg/m(2) (R-Dox) every 3 weeks i

28 e treated for six 3-week cycles of pegylated liposomal doxorubicin (20 mg/m(2)) plus interleukin-12 (

29 andomly assigned to receive either pegylated-liposomal doxorubicin (20 mg/m2) or the combination of d

30 The recommended phase II dose is liposomal doxorubicin 24 mg/m(2) on day 1 and gemcitabin

31 Patients received pegylated liposomal doxorubicin 24 mg/m2 intravenously on day 1, p

32 arily platinum resistant, 59.1% had received liposomal doxorubicin, 25% topotecan, 15.9% both agents,

33 in canine sarcomas treated with RF ablation-liposomal doxorubicin (3.7 cm +/- 0.6) compared with tha

34 ide 25 mg, bortezomib 1.3 mg/m(2), pegylated liposomal doxorubicin 30 mg/m(2), and dexamethasone 20/1

35 us carboplatin (AUC 5, day 1) plus pegylated liposomal doxorubicin (30 mg/m(2), day 1) every 4 weeks,

36 of every 28-day cycle; intravenous pegylated liposomal doxorubicin 40-50 mg/m(2) by body surface area

37 0 degrees C +/- 2, 5 minutes) followed by IV liposomal doxorubicin (5 mg per rabbit, 1 mg per rat) or

38 Patients received intravenous (I.V.) liposomal doxorubicin 50 mg/m2 every 3 weeks with a dose

39 Gylated liposomes (1295 MBq/kg), (e) (186)Re-liposomal doxorubicin (555 MBq/kg), (f) PEGylated liposo

40 r photodynamic damage, resulting in enhanced liposomal doxorubicin accumulation in tumors.

41 (38.9 ng/g +/- 8.0), and tumors treated with liposomal doxorubicin alone (43.9 ng/g +/- 6.7 for all r

42 mal) (n = 6), RF ablation alone (n = 6), and liposomal doxorubicin alone (n = 4).

43 with (186)Re-liposomal doxorubicin than with liposomal doxorubicin alone (tumor volume, 2.26 cm(3) +/

44 0.38; P < .001 vs all groups except (186)Re-liposomal doxorubicin alone).

45 e, 16.5 days +/- 3.2 for tumors treated with liposomal doxorubicin alone, and 26.6 +/- 5.3 days with

46 Stealth liposomal doxorubicin (Alzal Corp, Palo Alto, CA) has a

47 The use of RF ablation with liposomal doxorubicin and (186)Re-liposomal doxorubicin

48 nger than did animals that received combined liposomal doxorubicin and 70 degrees C RF ablation (P <.

49 Additionally, animals that received combined liposomal doxorubicin and 90 degrees C RF ablation survi

50 amycin (mTOR) inhibition in combination with liposomal doxorubicin and bevacizumab in patients with a

51 ines of conventional chemotherapy (pegylated liposomal doxorubicin and docetaxel) was treated with le

52 The individual received three cycles of liposomal doxorubicin and five doses of anti-programmed

53 ated ICLs extravasated better than PEGylated liposomal doxorubicin and fluorescent dextran and effici

54 The combination of liposomal doxorubicin and gemcitabine is an active and w

55 in barrier and increase the concentration of liposomal doxorubicin and PD-1 blocking antibodies (aPD-

56 +/- 1.5) was observed with a combination of liposomal doxorubicin and RF ablation (P <.001, for all

57 in tumors treated with temperature-sensitive liposomal doxorubicin and ultrasound hyperthermia.

58 Prior treatment with liposomal doxorubicin and/or gemcitabine was not allowed

59 (PegIntron and Pegasys), and nanoparticles (Liposomal-Doxorubicin and quantum-dots).

60 in (1 mg) alone, (c) RF ablation followed by liposomal doxorubicin, and (d) no treatment.

61 bination lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone (RVDD) in newly

62 se of less cardiotoxic alternatives, such as liposomal doxorubicin, and intensity-modulated radiation

63 These agents include gemcitabine, topotecan, liposomal doxorubicin, and prolonged oral etoposide.

64 Liposomal doxorubicin at doses of 40, 50, 60, and 80 mg/

65 acizumab, and temsirolimus (DAT) (N = 39) or liposomal doxorubicin, bevacizumab, and everolimus (DAE)

66 years; range, 37-79 years) were treated with liposomal doxorubicin, bevacizumab, and temsirolimus (DA

67 Liposomal doxorubicin, bevacizumab, and the mTOR inhibit

68 ly assigned to receive carboplatin-pegylated liposomal doxorubicin-bevacizumab (experimental group) a

69 Carboplatin-pegylated liposomal doxorubicin-bevacizumab is a new standard trea

70 osomal drugs (BNT162b2 vaccine and PEGylated liposomal doxorubicin), but not purified PEG2000, consis

71 reduce the sensitivity of HGSC cell lines to liposomal doxorubicin, but not to doxorubicin, whereas L

72 wed by intravenous administration of 1 mg of liposomal doxorubicin, (c) RF ablation followed by intra

73 Liposomal doxorubicin can be reliably delivered to liver

74 Intravenous administration of liposomal doxorubicin can improve RF ablation, since it

75 osed/anthracycline-naive patients, pegylated liposomal doxorubicin, CAPE, or Eribulin.

76 or reduced cardiac toxicity of non-pegylated-liposomal doxorubicin characterized by attenuation of RO

77 taining regimen versus carboplatin-pegylated liposomal doxorubicin combined with bevacizumab.

78 g or efficacy for H2009.1 tetrameric peptide liposomal doxorubicin, compared to control peptide and n

79 igned a fibronectin-targeting CREKA-modified liposomal doxorubicin (CREKA-Lipo-Dox) for the therapy o

80 for 5 minutes), (b) PEGylated liposomes, (c) liposomal doxorubicin, (d) (186)Re-PEGylated liposomes (

81 2) received 4 cycles of bortezomib-pegylated liposomal doxorubicin-dexamethasone, tandem melphalan (1

82 e impact of three weekly sessions of FUS and liposomal doxorubicin (DOX) in 9L rat glioma tumors.

83 herapeutic outcomes than clinically approved liposomal doxorubicin (Doxil) in HER2-overexpressing BT4

84 ining radiofrequency (RF) ablation with i.v. liposomal doxorubicin (Doxil) increases intratumoral dox

85 nced the efficacy of i.v. injected pegylated liposomal doxorubicin (Doxil).

86 Patients received 20 mg/m2 pegylated-liposomal doxorubicin (Doxil; Sequus Pharmaceuticals, In

87 ation of c-JO4 in combination with PEGylated liposomal doxorubicin/Doxil for ovarian cancer therapy.

88 tandard agents with rituximab plus pegylated liposomal doxorubicin (DR-COP) in an attempt to provide

89 rugs include topotecan, etoposide, pegylated liposomal doxorubicin, epirubicin, gemcitabine, altretam

90 y, demonstrates poor efficacy with PEGylated liposomal doxorubicin, even in sera with anti-PEG antibo

91 Use of RF ablation combined with liposomal doxorubicin facilitates increased tissue coagu

92 nimals were treated with intravenous (99m)Tc-liposomal doxorubicin followed by RF tumor ablation at a

93 s formulation than clinically representative liposomal doxorubicin for breast cancer treatment and pr

94 A novel liposomal doxorubicin formulation (Talidox(R)) with a sm

95 free doxorubicin and was superior to that of liposomal doxorubicin formulations.

96 Spheroids were dosed with liposomal doxorubicin, free doxorubicin, or media contro

97 dependent on the timing of administration of liposomal doxorubicin from 3 days before to 24 hours aft

98 ation with liposomal doxorubicin and (186)Re-liposomal doxorubicin further improved tumor control (tu

99 In HL-1 cells, non-pegylated liposomal-doxorubicin generated significantly less react

100 somal doxorubicin plus RF ablation > (186)Re-liposomal doxorubicin > liposomal doxorubicin plus RF ab

101 Stealth liposomal doxorubicin has activity in refractory epithel

102 Liposomal doxorubicin has substantial activity against o

103 his FUS technique to enhance the delivery of liposomal doxorubicin have a pronounced therapeutic effe

104 es were based on the clinical formulation of liposomal doxorubicin (i.e. DOXIL(R)) and were loaded wi

105 raphic findings demonstrated accumulation of liposomal doxorubicin in a peripheral rim of tumor adjac

106 gating TILT-123, pembrolizumab and PEGylated liposomal doxorubicin in a similar patient population is

107 Liposomal doxorubicin in combination with cyclophosphami

108 he clinical efficacy and safety of pegylated liposomal doxorubicin in combination with gemcitabine in

109 MTD) and define the toxic effects of stealth liposomal doxorubicin in combination with gemcitabine in

110 Pegylated liposomal doxorubicin in combination with gemcitabine is

111 developed to examine the activity of Stealth liposomal doxorubicin in platinum- and paclitaxel-refrac

112 e and electron microscopy after injection of liposomal doxorubicin in the hepatic artery, portal vein

113 score correlating with the concentration of liposomal doxorubicin in tumours and validated it in thr

114 Combining RF ablation with liposomal doxorubicin increases cell injury and apoptosi

115 ermined amount of the chemotherapeutic drug (liposomal doxorubicin) into the brain.

116 Pegylated liposomal doxorubicin is an effective treatment for HIV-

117 Pegylated-liposomal doxorubicin is more effective and less toxic t

118 MSI) and fluorescence imaging, showing that liposomal doxorubicin is stable to fluidic dosing and pe

119 oxicity; however, it remains unclear whether liposomal doxorubicin is therapeutically superior to fre

120 Herein, targeted liposomal doxorubicin (L-DXR) was functionalized with re

121 Studies have shown that liposomal doxorubicin (Lipo-DOX), a chemotherapy agent w

122 correlate with response, suggesting that the liposomal doxorubicin may evade this resistance mechanis

123 When RF ablation preceded administration of liposomal doxorubicin, mean intratumoral doxorubicin con

124 ion (n = 43), 1 mg of intravenously injected liposomal doxorubicin (n = 26), or combined therapy (n =

125 eport rationally engineered peptide-targeted liposomal doxorubicin nanoparticles that have an enhance

126 n > liposomal doxorubicin plus RF ablation > liposomal doxorubicin) of improved tumor growth control

127 Pegylated-liposomal doxorubicin offers a new alternative for treat

128 umors with C. novyi-NT plus a single dose of liposomal doxorubicin often led to eradication of the tu

129 terrogate the effects of dynamic dosing with liposomal doxorubicin on spheroid regions that would be

130 lator of heat shock proteins) alone and with liposomal doxorubicin on tumor growth and end-point surv

131 133 patients randomized to receive pegylated-liposomal doxorubicin, one achieved a complete clinical

132 three were treated with intravenous (99m)Tc-liposomal doxorubicin only.

133 vanced-stage KS, chemotherapy with pegylated liposomal doxorubicin or paclitaxel is the most common t

134 sus one of the approved drugs (eg, pegylated liposomal doxorubicin or topotecan) in platinum-resistan

135 on and direct intratumoral administration of liposomal doxorubicin, or (e) no treatment.

136 ight) or chemotherapy (paclitaxel, pegylated liposomal doxorubicin, or topotecan).

137 - 1.2 and 31.5 days +/- 3.0 without and with liposomal doxorubicin (P <.01).

138 ablation with intratumoral administration of liposomal doxorubicin (P <.05, compared with RF ablation

139 administration; and liposomal daunorubicin, liposomal doxorubicin, paclitaxel, and interferon-alpha

140 le-agent nonplatinum chemotherapy (pegylated liposomal doxorubicin, paclitaxel, gemcitabine, or topot

141 iting toxicities of bortezomib and pegylated liposomal doxorubicin (PegLD).

142 ct of cellular and microenvironmental MDR on liposomal doxorubicin performance than free doxorubicin.

143 of avelumab alone or avelumab plus pegylated liposomal doxorubicin (PLD) compared with PLD alone in p

144 valuated vintafolide combined with pegylated liposomal doxorubicin (PLD) compared with PLD alone.

145 We have investigated pegylated liposomal doxorubicin (PLD) in a clearly defined patient

146 safety of patupilone with those of pegylated liposomal doxorubicin (PLD) in patients with platinum-re

147 ncer agents 4-hydroxytamoxifen and pegylated liposomal doxorubicin (PLD) in the prevention and treatm

148 fficacy and safety of olaparib and pegylated liposomal doxorubicin (PLD) in this patient population.

149 itors, doxorubicin, etoposide, and pegylated liposomal doxorubicin (PLD) in vivo, utilizing ovarian c

150 Currently, pegylated liposomal doxorubicin (PLD) is a standard of care for tr

151 acy and safety of a combination of pegylated liposomal doxorubicin (PLD) plus bortezomib with bortezo

152 nter phase III study that compared pegylated liposomal doxorubicin (PLD) to the BV combination.

153 Since pegylated liposomal doxorubicin (PLD) was the most prevalent formu

154 acy and safety of trabectedin plus pegylated liposomal doxorubicin (PLD) with that of PLD alone in wo

155 II trial evaluated the bortezomib, pegylated liposomal doxorubicin (PLD), and dexamethasone combinati

156 ed Kaposi sarcoma is paclitaxel or pegylated liposomal doxorubicin (PLD); neither is routinely used i

157 l therapies had an observable trend ((186)Re-liposomal doxorubicin plus RF ablation > (186)Re-liposom

158 F ablation > (186)Re-liposomal doxorubicin > liposomal doxorubicin plus RF ablation > liposomal doxor

159 decreased in the group treated with (186)Re-liposomal doxorubicin plus RF ablation (0.54 cm(3) +/- 0

160 f) PEGylated liposomes plus RF ablation, (g) liposomal doxorubicin plus RF ablation, (h) (186)Re-PEGy

161 d liposomes plus RF ablation, or (i) (186)Re-liposomal doxorubicin plus RF ablation.

162 Combined RF ablation and liposomal doxorubicin retards tumor growth and may incre

163 In the healthy mouse, non-pegylated liposomal doxorubicin showed a minimal and non-significa

164 hil activation could be induced by PEGylated liposomal doxorubicin, suggesting that PEGylated lipids

165 trol of tumor growth was better with (186)Re-liposomal doxorubicin than with liposomal doxorubicin al

166 Subsequently, the dose (0.06-2.00 mg) of liposomal doxorubicin, the timing of administration (3 d

167 Combined therapy, as compared with liposomal doxorubicin therapy alone, was also associated

168 technique is able to identify both free and liposomal doxorubicin throughout the spheroid after just

169 show that increased delivery of intravenous liposomal doxorubicin to tumors combined with RF ablatio

170 therapy in the control arm (arm B; pegylated liposomal doxorubicin, topotecan, gemcitabine, once-week

171 therapy (once weekly paclitaxel or pegylated liposomal doxorubicin) until disease progression or toxi

172 The starting dose of liposomal doxorubicin was 20 mg/m(2) on day 1 only with

173 Stealth liposomal doxorubicin was administered at 50 mg/m(2) eve

174 Thermosensitive liposomal doxorubicin was administered systemically duri

175 A phase II study of liposomal doxorubicin was conducted in patients with ova

176 Liposomal doxorubicin was selected as a result of its su

177 ar scintigraphy, increased uptake of (99m)Tc-liposomal doxorubicin was visibly apparent in the ablate

178 vestigators selected chemotherapy (pegylated liposomal doxorubicin, weekly paclitaxel, or topotecan),

179 The responses achieved with liposomal doxorubicin were durable and maintained with m

180 ho received an anthracycline, dexrazoxane or liposomal doxorubicin were used in 78 of 1119 patients (

181 lphavbeta6-specific H2009.1 peptide targeted liposomal doxorubicin, which increased liposomal deliver

182 xicities of a new form of therapy, pegylated-liposomal doxorubicin, with standard combination chemoth

183 The regimen of IL-12 plus liposomal doxorubicin yielded rapid tumor responses and